Srikanth Nagalla, MD

Articles by Srikanth Nagalla, MD

Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNs

BySrikanth Nagalla, MD

April 24th 2020

Dr. Nagalla on the Utility of DOACs in Cancer-Associated Thrombosis

BySrikanth Nagalla, MD

April 17th 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

BySrikanth Nagalla, MD

March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

BySrikanth Nagalla, MD

March 26th 2020

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

BySrikanth Nagalla, MD

March 16th 2020

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Dr. Nagalla on the Utility of DOACs in MPN-Associated Thrombosis

BySrikanth Nagalla, MD

January 21st 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.